Financing channel feed – Endpoints News

Financing channel feed

BARDA bets $86M on ContraFect's PhIII bid against drug-resistant Staph

5 years ago

Monte Rosa pulls in $95M to test its 'molecular glues,' and the first target is GSPT1

5 years ago

Synthetic DNA player Touchlight scores $60M round to more than triple manufacturing capacity as mRNA gets hot

5 years ago

Arctic Vision collects $100M to bring US eye disease candidates overseas

5 years ago

Another SPAC is gearing up to go public, this time coming from Oleg Nodelman's EcoR1 Capital

5 years ago

AgomAb Therapeutics looks to take its 'true MET agonist' for broad use into the clinic with $74M round

5 years ago

Koch's 'disruptive' VC bets $110M on one of Flagship's new, big computational startups

5 years ago

China's YishengBio chronicles comeback story in Hong Kong IPO while plotting big moves in infectious diseases, cancer

5 years ago

Exclusive: Ready to exit 'quiet mode,' joint entity Ventyx debuts its immune modulator pipeline with $114M round

5 years ago

No more squinting at menus? Visus Therapeutics nabs $36M for presbyopia-correcting eye drop

5 years ago

Biotech IPO market looks to ramp back up as BMS partner Ikena and its immunometabolism therapies eye public offering

5 years ago

Not 3 weeks after taking Humacyte public, Rajiv Shukla launches another blank check company

5 years ago

An Array co-founder re-emerges as CEO of a small academic spinout, looking to remake an old class of cancer drugs

5 years ago

With $117M in fresh cash, Amunix paves path to the clinic for 'universal mask' prodrug on the hunt for HER2 tumors

5 years ago

BlackRock pushes Exscientia Series C to $100M as AI biotech boom continues

5 years ago

Peter Thiel-backed psychedelics player ATAI pulls in another nine-figure raise. But they're not ready to talk IPO — yet

5 years ago

Sofinnova Partners stays focused on late-stage deals with a new, $540M crossover fund

5 years ago

The 2021 top 100 biopharma investors: As the pandemic hit and IPOs boomed, VCs swung into action like never before

5 years ago

Fresh off $1B+ Merck deal, Janux locks down first private fundraise for its T cell engagers

5 years ago

A Jennifer Doudna-launched upstart nabs $115M for off-the-shelf CAR-Ts

5 years ago

As allogeneic cell therapy approaches flourish, Century loads up $160M to scale iPSC platform for CAR-T, CAR-NK

5 years ago

The next big biotech superstar? Paul Sekhri has some thoughts on that

5 years ago

OrbiMed, biopharma's biggest investor, closes $3.5B in three new private funds

5 years ago

Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria

5 years ago

First page Previous page 80 81 828384 85 86 Next page Last page